SCHEMBL6209437

SCHEMBL6209437

O=C(c1ccccc1)C1CCN(C(=O)CSc2ccc(C(F)(F)F)cn2)CC1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LIPE Q05469 2/20 0.55
ALDH1A1 P00352 5/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 2/20 0.51
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
THRB P10828 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD11B1 P28845 3/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
RAB9A P51151 1/20 0.46
MGLL Q99685 4/20 0.45
USP2 O75604 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1720793 0.73 HSD11B1 (0.81) KDM4EPOLBHSD11B1MEN1KMT2A
SCHEMBL4032772 0.72 ALDH1A1 (0.67) ALDH1A1KDM4EMAPTKMT2ARAB9A
SCHEMBL6212172 0.71 MGLL (0.63) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5649254 0.71 LIPE (1.00) LIPELMNAMAPTSMN1; SMN2MGLL
SCHEMBL10123278 0.70 GAA (0.61) ALDH1A1KDM4EPOLBLMNAMAPT
SCHEMBL14638795 0.70 HSD11B1 (0.71) LIPEKDM4EPOLBHSD11B1MEN1
SCHEMBL1000174 0.69 TRPV1 (0.57) ALDH1A1KDM4E
SCHEMBL6208978 0.69 HSD11B1 (0.84) POLBLMNAHSD11B1MEN1KMT2A
SCHEMBL5717582 0.68 ALDH1A1 (0.61) ALDH1A1KDM4ELMNAMAPTSMN1; SMN2
SCHEMBL14294137 0.68 BLM (0.62) ALDH1A1LMNAHSD11B1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors ASTRAZENECA AB (SE) 2005-11-17 US disclosed
EP-1556349-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS Astrazeneca AB (SE) 2005-07-27 EP disclosed
WO-2004033427-A1 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS ASTRAZENECA AB (SE) 2004-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256159-A1 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors HSD11B1, HSD3B1, P4HA1 LIPE 1856/4885ALDH1A1 14/4885KDM4E 1277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.